Physician profile
Mark D Vuolo
NPI 1104047547
$1,450.23
in general payments reported to CMS, 2019-2025
12 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2021: $191 · 2022: $125 · 2023: $399 · 2024: $162 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.85 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $225.86 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $214.89 | 2019-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $128.36 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $119.63 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $72.76 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $54.15 | 2019-2021 | |
| Lundbeck LLC | $38.82 | 2021-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.57 | 2023 | |
| Janssen Scientific Affairs, LLC | $32.78 | 2025 | Spravato |
| Allergan, INC. | $31.18 | 2019 | |
| Idorsia Pharmaceuticals US INC | $23.38 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vuolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.